- 12 月 3 日 10:00 AM - 5:00 PM
- I
- 台北漢來大飯店 · 鉑金廳 B
2025 亞洲醫療科技創新論壇
在MedTex,鏈結資本與創新力量,洞察AI世代的醫療新局與全球投資版圖。
[ 本論壇由生策中心、生策會與 永明生技投資 共同主辦 ]
邀集全球最具影響力的投資領域與前瞻醫療新創齊聚台灣
本次論壇將是您站在全球資本巨人肩上,洞察與布建產業成長與投資創新的最佳時局。
誠摯邀請國內投資家與企業領袖共聚,共啟國際投資未來嶄新布局。
瞄準先機
搶先掌握世界頂級創投的專業洞察,捕捉下一波醫療與健康投資趨勢。
連結全球資本
與國際投資人、企業及策略夥伴建立合作關係,開啟跨國連結與資金機會。
鎖定潛力新創
洞悉醫療與生技領域的新興突破新創,提前搶占下一波投資先機。
參加辦法
為維持論壇品質與座席安排,本論壇採邀請制,並提供午餐及茶點。每席次新台幣 5,000 元整,因席次有限,敬請於 11 月 20日前完成報名註冊,以利保留席位。
如擬推薦投資界或企業界領袖與會,敬請另行致電聯繫主辦單位協助安排:
(02)-26557888 #632 、#634、#673:洽施博士、陳博士、王博士。
為協助貴賓即時掌握論壇內容,現場備有 AI 文字即時同步翻譯。
活動日程
主題演講
開創新前沿:2026 年及未來的生命科學投資策略
• Noel Jee | Partner, Novo Holdings
10:10 – 10:40
AI 驅動的健康科技變革:投資人視角下的未來機會
• Yaron Daniely | General Partner, aMOON Fund
10:40 – 11:10
新創發表 - 第一場
AI 藥物研發與治療應用
1. Tom Miller | Co-Founder & CEO, Iambic Therapeutics
2. Gleb Kuznetsov | Co-Founder & CEO, Manifold Bio
3. Kevin Krause | President & CEO, Arrepath
4. Tim Craven | CEO, Myria Biosciences
11:10 – 12:30
專題論壇
投資未來醫療產業:洞察 2026 年的全球趨勢與潛在機會
1. Aiden Aceves ∣ Vice President, Insight Partners
2. Benjamin Kim ∣ Partner, Playground Global
3. Charles Lin ∣ Principle, Illumina ventures
4. Leighanne Oh ∣ Vice President, Ascenta Capital
13:30 – 15:00
新創發表 - 第二場
醫療機器人與數位健康創新的新世代
1. Matt Curran ∣ Co-Founder & CEO, Nanoflex Robotics
2. Aaron Timm ∣ CEO, OpenWater
15:00 – 15:30
新創發表 - 第三場
前瞻療法與藥物創新趨勢
1. Haim Belinson ∣ CEO, caVos Biotech
2. Yaron Sfadyah ∣ CEO, Coltac Therapeutics
3. Wyatt McDonnell ∣ Co-Founder & CEO, Infinimmune
4. Tim Craven ∣ CEO, Insamo
15:50 – 17:00
新創媒合以及工商洽談時段
17:00
國際創投
Noel Jee
Partner
Noel Jee is a Partner at Novo Holdings and broadly invests across healthcare and the life sciences. Previously a healthcare investor with Sofinnova Investments and Illumina Ventures, Noel honed his investment experience across therapeutics, life science tools, diagnostics, and healthcare platforms. Prior to his time in venture capital, he was a management consultant at L.E.K. Consulting.
Noel received his PhD in Chemistry and Chemical Biology from the University of California, San Francisco. Noel also holds a dual B.S. in Biochemistry and a B.S. in Neurobiology and Physiology from the University of Maryland, College Park, where he graduated with Honors.
Yaron Daniely
General Partner
Dr. Yaron Daniely is a General Partner at aMoon Fund, where he co-leads Velocity, aMoon’s early-stage investment fund. Prior to aMoon, Yaron was the President and CEO of Yissum, Hebrew University’s Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network. Before leading Yissum, he spent 14 years as a senior executive of private and NASDAQ-traded Biotech companies. Yaron earned his PhD from NYU, served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow at The Weizmann Institute for Science in Israel. He also holds an MBA from the Technion.
Aiden Aceves
Vice President
Aiden Aceves is a Vice President on the investments team at Insight. He joined the firm in 2021 to focus on investments in therapeutics and enabling technologies. Aiden was previously an associate at Vida Ventures, where he worked in the firm’s LA office making investments in innovative cell and gene therapy companies. Prior to becoming an investor, Aiden worked on founding and operating biotechnology companies in San Diego California, where he is based.
Aiden traces his academic lineage to Caltech, where he earned his doctorate in the lab of Dr. Steven Mayo, a leader in the space of computational protein engineering. Aiden received his B.S. in synthetic chemistry from the University of California, Riverside.
Ian Chiang
Ian is a Partner at Flare Capital, leading investments in healthcare and digital health companies such as Isaac Health, Knownwell, and Rx Redefined, and serving on the board of RightMove. He was previously a founding member and Senior Vice President at CareAllies, Cigna’s multi-payer provider services and home-based care business, where he led the development of technology-enabled services and strategic initiatives.
Ian is also a co-founder of startups including XcelDx and advised Scanwell Health, which was acquired by BD. He serves on the boards of the New England Venture Capital Association and Harvard Business School Healthcare Alumni Association, and is an Industry Advisor at Cornell Tech’s Precision Behavioral Health Initiative. Ian holds a B.Sc. in Biological Engineering from Cornell University and an MBA from Harvard Business School.
Benjamin Kim
Partner
Ben Kim is a Partner at Playground Global where he helps identify the founders and companies that are revolutionizing engineered biology. At Playground, he has sourced and led investments into companies including Atomic AI, Infinimmune, Insamo, Outpace Bio, and Manifold Bio. Prior to Playground, Ben was a PhD graduate student and an NSF Fellow at Stanford University, where he studied Bioengineering and Biomedical Engineering.
Charles H. Lin, PhD
Principle
Charles Lin is a biotech investor at Illumina Ventures, an independently managed venture capital fund based in California. He focuses on early-stage investments in Life Science Tools, Diagnostics, AgBio, and Therapeutics, and currently serves on the boards of Pluton Biosciences and NanoCellect Biomedical. Prior to joining Illumina Ventures, Charles was VP of Business Development and Marketing at Element Biosciences, where he helped secure US$80M in Series B financing and established key strategic partnerships.
Earlier in his career, he spent over a decade at Illumina, Inc., leading R&D and corporate development initiatives, including the US$100M acquisition of Edico Genome and the proposed US$1.2B acquisition of Pacific Biosciences. Charles holds a Ph.D. in Chemistry and Chemical Biology from Harvard University and a B.Sc. in Chemistry from National Taiwan University, with postdoctoral research conducted at UC San Diego and the Howard Hughes Medical Institute.
Leighanne Oh
Vice President
Leighanne Oh, MS is a Vice President at Ascenta Capital, focusing on discovering and evaluating biotech and life sciences investments. She previously invested at Novo Holdings and Sofinnova Investments, and began her career in healthcare investment banking at Jefferies, focusing on M&A, capital raising, and advisory work for biotech and pharmaceutical companies. Trained as a biomedical engineer, she also brings operational experience from GE Healthcare, and holds an M.S. and B.S.E. in Biomedical Engineering from Duke University.
Gleb Kuznetsov
Co-Founder and CEO
Gleb Kuznetsov, PhD, is the Co-Founder and CEO of Manifold Bio, a platform biotechnology company pioneering AI-guided protein design and mega-scale in vivo screening to unlock tissue-targeted medicines. He founded Manifold Bio after completing his PhD in the Harvard Biophysics program in the lab of George Church, where he developed new approaches for protein measurement and design by combining high-throughput biology, DNA sequencing, DNA synthesis, and machine learning technologies. At Manifold, Gleb focuses on shaping strategy, building world-class teams, leading business development, and driving the company’s vision forward.
Matt Curran
Chief Executive Officer and co-founder
Matt Curran is the Chief Executive Officer and co-founder of Nanoflex Robotics, a remote surgical robotic startup based in Switzerland that aims to make life-saving procedures more accessible.
Matt has more than two decades of experience in the medical device industry. Most recently, he served as Medtronic Vice President of Cranial and Spinal Therapies for the EMEA region, where he brought the company’s first surgical robots to market.
During his time at Medtronic, he held leadership roles in different regions, including the United Kingdom, EMEA, Southeast Asia and Korea, primarily within the company’s Neurology, Spine and Pain Therapies, and Cardiac divisions. In these roles, he focused on coaching and developing multicultural teams, all while overseeing billion-dollar business units.
Matt’s passion for groundbreaking, impactful medical technologies led him to co-found Nanoflex Robotics with Christophe Chautems and Bradley Nelson in 2021, with the aim of expanding access to critical interventions through remote surgical robotics. Matt is a member of the Board of Directors at Aleva Neurotherapeutics and is actively involved in coaching programs, including supporting minority groups and early career professionals.
Matt earned an MBA from the University of Edinburgh Business School in Edinburgh, Scotland. He lives in St-George, Switzerland with his wife and two children. In his free time Matt enjoys running and kayaking.
Haim Belinson
CEO
Dr. Haim Belinson received a PhD. in neurobiology from the Tel Aviv University in Israel. Following postdoctoral training at the Department of Pediatrics, Institute for Human Genetics, UCSF, San Francisco, CA. where he studied brain development and the brain gut axis in the context of autism spectrum disorder, he joined Teva Pharmaceutical where he utilized broad neuroscience scientific expertise and lead pharmacology preclinical development of drugs for neurodegenerative diseases, neuropsychiatry and pain. At Teva, he dealt with both the scientific aspects as well as leading various stages of drug development from ideation to PhIII. Since 2018, Dr. Belinson led Bsense Bio Therapeutics as its CSO and later CEO in the development program of small molecule targeting sensory hyperexcitability from ideation to clinical candidate nomination. In 2025, Dr. Belinson joined caVos Biotherapeutics as its CEO, to lead the innovative approach of developing novel therapeutics based on naturally occurring resistance mechanisms.
Dr. Belinson has over 20 years of experience in R&D, spanning pharmaceutical R&D, target identification/validation, behavioral pharmacology and PK/PD.
Yaron Sfadyah
CEO, Coltac Therapeutics
With over a decade of global experience in managerial and business development roles, Yaron has worked across industries including medical devices, pharmaceuticals, semiconductors, and foodtech. He specializes in guiding products from R&D through international collaborations and successful commercialization across diverse markets.
Yaron lives by the motto: “We don’t stop playing because we grow old; we grow old because we stop playing” (George Bernard Shaw), later echoed by LEGO CEO Jørgen Vig Knudstorp. He believes this mindset applies equally to business—where value and technology spark engagement, but trust, creativity, and play sustain it. For Yaron, even the most complex challenges are best solved when creativity and enjoyment are part of the process.
Outside of work, Yaron is an avid (amateur) beach volleyball player and podcast host. He also helps lead a Tel Aviv-based group that organizes bi-monthly events, where speakers share personal stories of failure, fostering a culture of learning and resilience.
This blend of professional expertise and personal passions shapes Yaron’s unique perspective on both business and life.
—
Coltac Therapeutics is a biotech startup, backed by aMoon and IBF, dedicated to developing the next generation of molecular glues for targeted protein degradation.
The company is advancing three programs: two high-value oncology targets and one non-oncology, leveraging molecular glue hits discovered through its proprietary BOND+ platform.
BOND+ platform combines virtual screening with high-throughput, positive-signal bacterial validation, enabling a rapid and efficient transition to chemical optimization and mammalian cell testing.
—
Advancing Molecular Glue Discovery Through a Positive-Signal Bacterial Screening Platform |
|
Wyatt McDonnell
Co-Founder, CEO, & Chairman of the Board of Directors
Wyatt McDonnell is Co-Founder, CEO, & Chairman of the Board of Directors @ Infinimmune, a biotechnology company utilizing natural immunity to transform natural antibodies into safer and more effective drugs for complex diseases. Previously, Wyatt developed 10x Genomics’ first therapeutic antibodies and core immunology intellectual property behind three commercial products to interrogate the immune repertoire. He has co-authored 31 peer-reviewed papers in journals including Nature, Cell, and Nature Medicine, and 19 published patents in relation to immunobiology, genomics, and disease. He has been invited to speak at conferences including PEGS, the Keystone Symposia, the World Vaccine Congress, and PMWC.
新創發表
來自 AI、數位醫療與生技領域的前沿新創齊聚一堂,揭示正在重新定義醫療未來的創新技術。